Breakout Stocks of Week 14 @ FRA

NASDAQ was down last week (week 13) by -3.26% ending at 20,948.36 points after falling -705.35 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Klöckner & Co SE FRA:KCO. This stock has had a buy signal since Nov 24, 2025 when the price was 5.52€ and is so far up 118.48% to 12.06€. Some other companies are on our watchlist to, among these are Spdr S&p 400 Us Mid Cap Ucits Etf FRA:SPY4 Xtrackers Msci World Consumer Staples Ucits Etf FRA:XDWS Ishares Msci World Small Cap Ucits Etf FRA:IUSN and Rio Tinto Group FRA:RIO1 which all got a breakout pattern emerging.

Date Company Price Week 14
Mar 27, 2026 Klöckner & Co Se 12.06€ 12.22€ 1.33%
Mar 27, 2026 Spdr S&p 400 Us Mid Cap Ucits Etf 89.81€ 91.59€ 1.98%
Mar 27, 2026 Xtrackers Msci World Consumer Staples Ucits Etf 46.31€ 46.49€ 0.389%
Mar 27, 2026 Ishares Msci World Small Cap Ucits Etf 7.86€ 8.09€ 2.84%
Mar 27, 2026 Rio Tinto Group 75.45€ 81.38€ 7.86%

Klöckner & Co SE

FRA:KCO Strong Buy Candidate Score: 7.72
Strong Buy Candidate Score: 7.72 Mar 27, 2026

Klöckner & Co SEThe Klöckner & Co SE stock price gained 1.86% on the last trading day (Friday, 27th Mar 2026), rising from 11.84€ to 12.06€. During the last trading day the stock fluctuated 4.62% from a day low at 11.70€ to a day high of 12.24€. The price has been going up and down for this period, and there has been a 1.17% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 545 thousand more shares were traded than the day before. In total, 905 thousand shares were bought and sold for approximately 10.92€ million.

Klöckner & Co SE holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.

About Klöckner & Co SE:
Klöckner & Co SE, through its subsidiaries, distributes steel and metal products. It operates through three segments: Kloeckner Metals US, Kloeckner Metals EU, and Kloeckner Metals Non-EU. The company's product portfolio includes flat steel products; long steel products; tubes and hollow sections; stainless steel and high-grade steel; aluminum products; and special products for building installations, roof and wall construction, and water supply. It also provides various services, including cutting and splitting of steel strips; forming and manufacturing of pressed parts; CNC turning/milling; 2D/3D tube laser cutting; laser and water jet cutting; structural steel processing; plasma and oxy-fuel cutting; shot blasting and primer painting; and sawing/drilling/rounding off. In addition, the company offers warehousing, logistics, and materials management services. It serves small to medium-sized steel and metal consumers, primarily from the construction industry, as well as machinery and mechanical engineering industries; and supplies intermediate products for the automotive, shipbuilding, and consumer goods industries. The company was founded in 1906 and is headquartered in Duisburg, Germany.

Spdr S&p 400 Us Mid Cap Ucits Etf

FRA:SPY4 Hold/Accumulate Score: 0.471
Hold/Accumulate Score: 0.471 Mar 27, 2026

The Spdr S&p 400 Us Mid Cap Ucits Etf ETF price fell by -1.30% on the last day (Friday, 27th Mar 2026) from 90.99€ to 89.81€. During the last trading day the ETF fluctuated 1.52% from a day low at 89.49€ to a day high of 90.85€. The price has risen in 6 of the last 10 days but is still down by -0.76% for this period. Volume fell on the last day along with the ETF, which is actually a good sign as volume should follow the ETF. On the last day, the trading volume fell by -3 thousand shares and in total, 24 thousand shares were bought and sold for approximately 2.12€ million.

Spdr S&p 400 Us Mid Cap Ucits Etf holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

Xtrackers Msci World Consumer Staples Ucits Etf

FRA:XDWS Hold/Accumulate Score: 0.267
Hold/Accumulate Score: 0.267 Mar 27, 2026

The Xtrackers Msci World Consumer Staples ETF price gained 0.303% on the last trading day (Friday, 27th Mar 2026), rising from 46.17€ to 46.31€. It has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the ETF fluctuated 1.07% from a day low at 45.82€ to a day high of 46.31€. The price has been going up and down for this period, and there has been a -3.95% loss for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 35 thousand more shares were traded than the day before. In total, 43 thousand shares were bought and sold for approximately 2.01€ million.

Xtrackers Msci World Consumer Staples holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

Ishares Msci World Small Cap Ucits Etf

FRA:IUSN Hold/Accumulate Score: 0.254
Hold/Accumulate Score: 0.254 Mar 27, 2026

The Ishares Msci World Small Cap Ucits Etf ETF price fell by -1.35% on the last day (Friday, 27th Mar 2026) from 7.97€ to 7.86€. During the last trading day the ETF fluctuated 1.48% from a day low at 7.85€ to a day high of 7.96€. The price has been going up and down for this period, and there has been a -2.04% loss for the last 2 weeks. Volume has increased on the last day by 479 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 1 million shares were bought and sold for approximately 8.79€ million.

Ishares Msci World Small Cap Ucits Etf holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

Rio Tinto Group

FRA:RIO1 Hold/Accumulate Score: 0.148
Hold/Accumulate Score: 0.148 Mar 27, 2026

Rio Tinto GroupThe Rio Tinto Group stock price gained 1.32% on the last trading day (Friday, 27th Mar 2026), rising from 74.47€ to 75.45€. During the last trading day the stock fluctuated 2.73% from a day low at 73.57€ to a day high of 75.58€. The price has risen in 6 of the last 10 days but is still down by -2.25% for this period. Volume fell on the last day by -9 thousand shares and in total, 54 thousand shares were bought and sold for approximately 4.05€ million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

Rio Tinto Group holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

About Rio Tinto Group:
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

GOLDEN STAR
Ticker Change Signal Date
NESR
$25.06
0.439% Jun 22
IDYA
$28.98
25.19% Jun 12
PHM
$118.49
14.53% Jun 10
DHI
$146.71
13.50% Jun 10
EAT
$140.46
20.94% Jun 05
.

StockInvest.usStock Podcast